ClinicalTrials.gg
CompletedNCT00158860Updated Feb 15, 2019Results posted

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

A Phase 4 interventional study of Valaciclovir and Placebo in Herpes Genitalis, sponsored by GlaxoSmithKline. Completed at 72 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.

Enrollment
Largest of 11
384 · median 50
Started
2004
with 2 others
Phase 4
6 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
4 of 14
GlaxoSmithKline

Among the 14 studies testing valacyclovir in Herpes Genitalis, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2004, is one of 6 in phase 4, and was the 7th registered.

Herpes Genitalis

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

Browse Herpes Genitalis studies →

Open to participants now

None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing valacyclovir in Herpes Genitalis as a file.
02

Study summary

Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more likely to produce frequent recurrences of GH lesions. Evidence suggests that there are advantages to using suppressive vs. episodic treatment, which include increased intervals between the pain and discomfort of genital herpes recurrences. Therefore, this study will collect safety and efficacy data on suppressive therapy with valaciclovir in subjects newly diagnosed with HSV-2 genital herpes.

03

Conditions studied

  • Herpes Genitalis

Browse trials for

Keywords

  • VALTREX®
  • valaciclovir
  • genital herpes
  • HSV-2
  • suppression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In overall general good health.
  • Females can enter and participate in this study if they are of non- (i.e., physiologically incapable of becoming pregnant) or if of childbearing potential, has a negative pregnancy test (urine) at screening and agrees to use GSK stipulated methods.
  • Must be newly diagnosed with a first recognized episode of GH at the time of the Screening Visit or within 3 months prior to the Screening Visit.

Exclusion criteria

Exclusion criteria:

  • Known or suspected to be (e.g., subjects receiving immunosuppressive therapy or chemotherapy for , or are seropositive for ).
  • Received an drug in the 30 days prior to the study.
  • Receiving systemic antiviral or immunomodulatory treatments.
  • Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug.
  • impaired renal function as defined by a \<30 ml/min, calculated using the Cockcroft-Gault formula.
  • Clinically significant impaired hepatic function defined as an (alanine transaminase) level > 5 times the normal upper limit.
  • Subjects with active liver disease.
  • Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations.
  • Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir or valganciclovir.
  • Subjects with malabsorption or vomiting syndrome or other gastrointestinal dysfunction that might impair drug pharmacokinetics.
  • Women contemplating pregnancy within the duration of the study drug dosing period.
  • Women who are pregnant and/or nursing mothers
  • Current history of alcohol or drug abuse.
  • Received suppressive (daily) therapy for genital herpes prior to enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
384 participants (actual)

Study arms

  • Experimental
    Valaciclovir

    Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).

    Drug: Valaciclovir

  • Placebo comparator
    Placebo

    Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Time to First GH Recurrence

    Diary cards were issued to the participants during randomization visit for recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant. The percentage of participants with time to first GH recurrence was based on Kaplan-Meier estimates. Confidence intervals for differences in proportions was calculated using the standard error for the Kaplan-Meier estimate derived using Greenwood's formula.

    Time frame: Day 168

Secondary outcomes

  1. Mean Number of GH Recurrences Per Month Within the 6-month Study Period

    Mean number of GH recurrence reaching macular/papular stage per month was reported. Diary cards were issued to the participants during randomization visit for the recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant.

    Time frame: Up to Day 168

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as any untoward medical occurrence that, at any dose results in death, was life-threatening, required hospitalization or prolongation of hospitalization, results in disability/incapacity, was a congenital anomaly/birth defect or medically significant.

    Time frame: Upto Day 168

  3. Percentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months

    Diary cards were issued to the participants during randomization visit for recording HSV outbreak within 6-momths. HSV outbreak was assessed after review of the diary card and discussion with the participant. The percentage of participants who had first oral HSV outbreak at 6-months was reported.

    Time frame: Day 168

  4. Number of Isolates With Resistance to Acyclovir (ACV)

    Culture samples were tested for AVC-susceptibility by the analytical laboratory. Re-testing of the ACV resistant isolates was carried out to check if the half maximal inhibitory concentration (IC-50s) for all the ACV resistant isolates were within the expected errors of 2.0 microgram per milliliters (mcg/ml) cut-off for the plaque reduction assay. Those isolates that confirm to be resistant in repeat assays were considered as resistant to ACV.

    Time frame: Day 168

07

Results

Posted Feb 15, 2019

Participant flow

The study was conducted in 74 centers in the Unites States, Canada, Argentina, Brazil, and Chile.

Participant flow — Overall Study
MilestonePlaceboValaciclovir 1g QD
Started128255
Completed93184
Not completed3571
Withdrew: Adverse event36
Withdrew: Lost to follow-up1117
Withdrew: Protocol violation823
Withdrew: Withdrawal by subject717
Withdrew: Moving out of state10
Withdrew: Pregnancy33
Withdrew: Sponsor stopped study22
Withdrew: Sponsor request01
Withdrew: Lost to follow up but returned per gsk01
Withdrew: Closed per sponsor01

Outcome measures

PrimaryPercentage of Participants With Time to First GH Recurrence

Diary cards were issued to the participants during randomization visit for recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant. The percentage of participants with time to first GH recurrence was based on Kaplan-Meier estimates. Confidence intervals for differences in proportions was calculated using the standard error for the Kaplan-Meier estimate derived using Greenwood's formula.

Time frame:
Day 168
Reported as:
Number · Percentage of participants
Percentage of Participants With Time to First GH Recurrence
Percentage of participantsPlaceboValaciclovir 1g QD
Percentage of Participants With Time to First GH Recurrence4371
Statistical analysis
  • Placebo vs Valaciclovir 1g QD · Log Rank · p = <0.001 · Kaplan-meier estimates: 27.3 · 95% CI 16.0 to 38.6
  • Placebo vs Valaciclovir 1g QD · Log Rank · p = <0.001 · Hazard ratio (hr): 0.401 · 95% CI 0.282 to 0.570
SecondaryMean Number of GH Recurrences Per Month Within the 6-month Study Period

Mean number of GH recurrence reaching macular/papular stage per month was reported. Diary cards were issued to the participants during randomization visit for the recording GH recurrences. HSV recurrences since the last visit was assessed after review of the diary card and discussion with the participant.

Time frame:
Up to Day 168
Reported as:
Mean · Number of recurrences
Mean Number of GH Recurrences Per Month Within the 6-month Study Period
Number of recurrencesPlaceboValaciclovir 1g QD
Mean Number of GH Recurrences Per Month Within the 6-month Study Period0.48 ± 1.8600.11 ± 0.254
Statistical analysis
  • Placebo vs Valaciclovir 1g QD · Wilcoxon rank sum test · p = <0.001
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as any untoward medical occurrence that, at any dose results in death, was life-threatening, required hospitalization or prolongation of hospitalization, results in disability/incapacity, was a congenital anomaly/birth defect or medically significant.

Time frame:
Upto Day 168
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboValaciclovir 1g QD
Any AEs98185
Any SAEs43
SecondaryPercentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months

Diary cards were issued to the participants during randomization visit for recording HSV outbreak within 6-momths. HSV outbreak was assessed after review of the diary card and discussion with the participant. The percentage of participants who had first oral HSV outbreak at 6-months was reported.

Time frame:
Day 168
Reported as:
Number · Percentage of participants
Percentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months
Percentage of participantsPlaceboValaciclovir 1g QD
Percentage of Participants With Time to First Oral Herpes Simplex Virus (HSV) Outbreak Within 6-months1114
SecondaryNumber of Isolates With Resistance to Acyclovir (ACV)

Culture samples were tested for AVC-susceptibility by the analytical laboratory. Re-testing of the ACV resistant isolates was carried out to check if the half maximal inhibitory concentration (IC-50s) for all the ACV resistant isolates were within the expected errors of 2.0 microgram per milliliters (mcg/ml) cut-off for the plaque reduction assay. Those isolates that confirm to be resistant in repeat assays were considered as resistant to ACV.

Time frame:
Day 168
Reported as:
Number · Number of isolates
Number of Isolates With Resistance to Acyclovir (ACV)
Number of isolatesPlaceboValaciclovir 1g QD
Number of Isolates With Resistance to Acyclovir (ACV)00

Adverse events

Collected over AEs were collected up to end of study (Day 168).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/128 (0%)4/128 (3.1%)75/128 (58.6%)
Valaciclovir 1g QD1/255 (0.4%)3/255 (1.2%)138/255 (54.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboValaciclovir 1g QD
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/1281/255
HypokalaemiaMetabolism and nutrition disorders1/1280/255
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1280/255
AppendicitisInfections and infestations0/1281/255
Gun shot woundInjury, poisoning and procedural complications0/1281/255
Most frequent other events
Most frequent other events
EventPlaceboValaciclovir 1g QD
HeadacheNervous system disorders39/12859/255
NasopharyngitisInfections and infestations13/12835/255
Vulvovaginal mycotic infectionInfections and infestations12/12816/255
Herpes simplexInfections and infestations8/12822/255
DysmenorrhoeaReproductive system and breast disorders11/12816/255
NauseaGastrointestinal disorders10/12811/255
Urinary tract infectionInfections and infestations9/1287/255
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders4/12814/255
InfluenzaInfections and infestations7/1287/255
Back painMusculoskeletal and connective tissue disorders6/12813/255

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboValaciclovir 1g QDTotal
Mean32.2 ± 11.5230.9 ± 10.4831.3 ± 10.84
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboValaciclovir 1g QDTotal
Female92176268
Male3679115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboValaciclovir 1g QDTotal
Race — American Hispanic173451
Race — Arabic/North African022
Race — Black3984123
Race — East & South East Asian022
Race — White/Caucasian68125193
Race — Unknown4812
08

Study locations

72 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Tucson, Arizona 85710, United States
  • GSK Investigational Site
    Anaheim, California 92805, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Davis, California 95616, United States
  • GSK Investigational Site
    Fair Oaks, California 95628, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Sacramento, California 95816, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    San Francisco, California 94102, United States
  • GSK Investigational Site
    Santa Ana, California 92704, United States
  • GSK Investigational Site
    Hartford, Connecticut 06012, United States
  • GSK Investigational Site
    New Britain, Connecticut 06052, United States
  • GSK Investigational Site
    Clearwater, Florida 33759, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Melbourne, Florida 32901, United States
  • GSK Investigational Site
    Palm Springs, Florida 33461, United States
  • GSK Investigational Site
    Venice, Florida 34285, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Alpharetta, Georgia 30005, United States
  • GSK Investigational Site
    Atlanta, Georgia 30310, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Springfield, Illinois 62702, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202 - 5124, United States
  • GSK Investigational Site
    South Bend, Indiana 46601, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Taunton, Massachusetts 02780, United States
  • GSK Investigational Site
    Portage, Michigan 49024, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89128, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Endicott, New York 13760, United States
  • GSK Investigational Site
    Stony Brook, New York 11794-8091, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • GSK Investigational Site
    East Providence, Rhode Island 02914, United States
  • GSK Investigational Site
    Memphis, Tennessee 38104, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
  • GSK Investigational Site
    Austin, Texas 78746, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Georgetown, Texas 78626, United States
  • GSK Investigational Site
    Houston, Texas 77058, United States
  • GSK Investigational Site
    San Antonio, Texas 78205, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    La Crosse, Wisconsin 54601, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53209-0996, United States
  • GSK Investigational Site
    Waukesha, Wisconsin 53186, United States
  • GSK Investigational Site
    Buenos Aires, 1221, Argentina
  • GSK Investigational Site
    Buenos Aires, C1114AAP, Argentina
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90470-340, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20 551-030, Brazil
  • GSK Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1S 0G8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5V 2T3, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Québec, G1S 2L6, Canada
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7580206, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8380456, Chile
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2004 to primary completion in Jul 2006, 25 months.

Results were first posted in Feb 2019, 12 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Jun 21, 2004
Primary completionActual
Jul 26, 2006
CompletionActual
Jul 26, 2006
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00158860
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jun 21, 2004
Primary completion
Jul 26, 2006
Completion
Jul 26, 2006
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion